Collaboration, License and Other Strategic Agreements (Details) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended				12 Months Ended
	Apr. 03, 2017	Feb. 28, 2017	Jun. 30, 2013	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Agreements
Shares issued in connection with Endoceutics License Agreement									$ 13,500
Endoceutics, Inc.
Collaborative Agreements
Payments related to collaborative arrangement	$ 50,000
Number of shares issued under arrangement	600,000
Shares issued in connection with Endoceutics License Agreement	$ 13,500							$ 0	12,555	$ 0
Future contingent payments (up to)								0	$ 9,300	$ 0
Consideration recorded						$ 83,500
IPR&D expense						5,800
Palatin Technologies, Inc.
Collaborative Agreements
Payments related to collaborative arrangement		$ 60,000					$ 60,000
Out-of-pocket expenses (up to)		$ 25,000
Abeona Therapeutics Inc.
Collaborative Agreements
Payments related to collaborative arrangement			$ 3,300
Intrarosa | Endoceutics, Inc.
Collaborative Agreements
Payments related to collaborative arrangement					$ 6,000
Out-of-pocket expenses (up to)					20,000
Intrarosa | Endoceutics, Inc. | Developed technology rights
Collaborative Agreements
Finite-lived intangible assets						$ 77,700
Intrarosa | Endoceutics, Inc. | Delivery of Intrarosa Launch Quantities
Collaborative Agreements
Payments related to collaborative arrangement					$ 10,000
Intrarosa | Endoceutics, Inc. | First Anniversary of Closing
Collaborative Agreements
Future contingent payments (up to)								10,000
Intrarosa | Endoceutics, Inc. | Tiered Royalties
Collaborative Agreements
Potential milestone payment, triggering event, sales	$ 150,000							$ 150,000
Royalty percentage, maximum	25.00%							25.00%
Net sales threshold, future contingent payments	$ 1,000,000							$ 1,000,000
Period after first commercial sale	10 years							10 years
Intrarosa | Endoceutics, Inc. | First Sales Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)	$ 15,000							$ 15,000
Potential milestone payment, triggering event, sales	150,000							150,000
Intrarosa | Endoceutics, Inc. | Second Sales Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)	30,000							30,000
Potential milestone payment, triggering event, sales	300,000							300,000
Intrarosa | Endoceutics, Inc. | Third Sales Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)	850,000							850,000
Potential milestone payment, triggering event, sales	$ 500,000							500,000
Vyleesi Products | Palatin Technologies, Inc. | Tiered Royalties
Collaborative Agreements
Period after first commercial sale		10 years
Vyleesi Products | Palatin Technologies, Inc. | First Sales Milestone Achievement
Collaborative Agreements
Future contingent payments (up to)		$ 25,000
Potential milestone payment, triggering event, sales		250,000
Vyleesi Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, Acceptance by U.S.Food And Drug Administration of New Drug Application
Collaborative Agreements
Payments related to collaborative arrangement				$ 20,000				20,000
Vyleesi Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, U.S.Food and Drug Administration Approval
Collaborative Agreements
Future contingent payments (up to)		60,000						60,000
Vyleesi Products | Palatin Technologies, Inc. | Achievement of Certain Annual Sales Milestones Over Course of License Agreement
Collaborative Agreements
Future contingent payments (up to)		$ 300,000						$ 300,000